Document is current
Any future updates will be listed below
-
Authors
Blume, Cornelia http://orcid.org/0000-0001-6133-7318
Jackson, Claire L. http://orcid.org/0000-0002-1200-0935
Spalluto, Cosma Mirella
Legebeke, Jelmer http://orcid.org/0000-0003-1194-8959
Nazlamova, Liliya
Conforti, Franco
Perotin, Jeanne-Marie
Frank, Martin
Butler, John
Crispin, Max http://orcid.org/0000-0002-1072-2694
Coles, Janice
Thompson, James
Ridley, Robert A.
Dean, Lareb S. N.
Loxham, Matthew
Reikine, Stephanie
Azim, Adnan
Tariq, Kamran
Johnston, David A.
Skipp, Paul J.
Djukanovic, Ratko
Baralle, Diana
McCormick, Christopher J.
Davies, Donna E. http://orcid.org/0000-0002-5117-2991
Lucas, Jane S. http://orcid.org/0000-0001-8701-9975
Wheway, Gabrielle http://orcid.org/0000-0002-0494-0783
Mennella, Vito http://orcid.org/0000-0002-4842-9012
-
Funding
Funding for this research was provided by:
AAIR Charity (AAIR/01/ACE2/2020, AAIR/01/ACE2/2020, AAIR/01/ACE2/2020, AAIR/01/ACE2/2020)
- License Information
-
More Information
Article History
Received: 26 July 2020
Accepted: 1 December 2020
First Online: 11 January 2021
Competing interests
: D.E.D. and R.D. are co-founders, shareholders and consultants to the university spin-off company, Synairgen, which is developing inhaled IFN-β for treatment of respiratory viral infections, including SARS-CoV2 (COVID-19). S.R. is an employee of, and shareholder in, Nuclera Nucleic Acids Ltd. Other authors declare no competing interests.
Free to read: This content has been made available to all.
